N1-(4-异丙苯基)-2-氯乙胺 | 1527-61-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N1-(4-异丙苯基)-2-氯乙胺
• 中文别名: N1-(4-异丙基苯基)-2-氯乙酰胺
• 英文名称: 2-chloro-N-(4-isopropylphenyl)acetamide
• 英文别名: α-chloro-N-(p-isopropylphenyl)acetamide；2-chloro-N-(4-propan-2-ylphenyl)acetamide
• CAS: 1527-61-3
• 化学式: C₁₁H₁₄ClNO
• mdl: MFCD00084931
• 分子量: 211.691
• InChiKey: NBPOAZHKOZEYOV-UHFFFAOYSA-N

物化性质

• 熔点：
  132 °C
• 沸点：
  356.0±35.0 °C(Predicted)
• 密度：
  1.150±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S24/25
• 海关编码：
  2924299090
• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温

SDS

Name:	N1-(4-isopropylphenyl)-2-chloroacetamide 97% Material Safety Data Sheet
Synonym:	N-Chloroacetyl-4-isopropylanilin
CAS:	1527-61-3

Section 1 - Chemical Product MSDS Name:N1-(4-isopropylphenyl)-2-chloroacetamide 97% Material Safety Data Sheet
Synonym:N-Chloroacetyl-4-isopropylanilin

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
1527-61-3	N1-(4-Isopropylphenyl)-2-chloroacetami	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 1527-61-3: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: off-white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 132 - 135 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H14ClNO
Molecular Weight: 212

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, reducing agents.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 1527-61-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
N1-(4-Isopropylphenyl)-2-chloroacetamide - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 1527-61-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 1527-61-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 1527-61-3 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N1-(4-异丙苯基)-2-氯乙胺 在 sodium azide 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成 2-azido-N-(4-isopropylphenyl)acetamide
  参考文献：
  名称：

  使用碘-膦电荷转移复合物直接固定 CO2 用于乙内酰脲同位素标记

  摘要：

  在此，我们报道了一种通过三甲基-λ 5 -二碘化膦介导的羰基插入直接从 CO 2中同位素标记乙内酰脲的方法。该方法适用于不同底物的13 C-标记，并在 PET 成像设备中用于11 C-标记，用于合成放射性示踪剂。制剂中含有乙内酰脲的候选药物在 30 分钟内实现了 90% 的分离产率和 89% 的放射化学产率，具有高摩尔活性 (>400 MBq nmol -1 )。

  DOI：

  10.1039/d2cc01754g
• 作为产物：
  描述：

  4-异丙基苯胺 、 氯乙酰氯 在 sodium acetate 作用下， 以 溶剂黄146 、 水 为溶剂， 反应 2.0h， 生成 N1-(4-异丙苯基)-2-氯乙胺
  参考文献：
  名称：

  具有异恶唑[5,4-d]嘧啶-4（5H）-1支架的新型选择性IDO1抑制剂。

  摘要：

  吲哚胺2，3-二加氧酶1（IDO1）是几种病理状况，尤其是癌症的免疫调节中的有希望的目标。在这里，我们目前与新型异恶唑并[5,4 - d ]嘧啶-4（5 H）-一个支架的一系列IDO1抑制剂的合成。使用6步或7步合成程序制备了一个有针对性的文库，以系统地研究所述支架的构效关系。化学驱动的修改导致我们我们具有最佳的类抑制剂的发现p三氟甲基（23），p -环己基（32），或p甲氧基羰基（20，39）IC 50值在低微摩尔范围内的取代苯胺部分。除hIDO1以外，还测试了化合物对吲哚胺2,3-双加氧酶2和色氨酸双加氧酶的抑制作用，发现它们对hIDO1具有选择性。因此，我们的结果证明了对IDO1选择性异恶唑并[5,4- d ]嘧啶4（5 H）-one抑制剂的成功研究，它定义了一种有前途的化学探针，并带有用于进一步开发强效小分子免疫调节剂的新型支架。

  DOI：

  10.3390/ph14030265

文献信息

• 野黄芩素衍生物及其制备方法和应用
  申请人：中国药科大学

  公开号：CN106883244B

  公开（公告）日：2018-11-30

  本发明公开了如式I所示的野黄芩素衍生物。本发明还公开了野黄芩素衍生物的制备方法。本发明还公开了野黄芩素衍生物在制备抗肿瘤药物方面的应用。本发明以野黄芩素为起始原料，合成了一系列A环具有苯并二氧六环结构，B环4’位连接脂溶性基团和水溶性基团的野黄芩素衍生物，该合成方法简单，具有较好的可操作性和反应收率。本发明公开的野黄芩素衍生物具有抑制多种肿瘤细胞增殖活性，活性优于或相当于野黄芩素，有望开发成为抗肿瘤药物。
• Combined structure- and ligand-based virtual screening aiding discovery of selenoglycolicamides as potential multitarget agents against Leishmania species
  作者：José Alixandre de Sousa Luis、Helivaldo Diógenes da Silva Souza、Bruno Freitas Lira、Francinara da Silva Alves、Petrônio Filgueiras de Athayde-Filho、Tatjana Keesen de Souza Lima、Juliana Câmara Rocha、Francisco Jaime Bezerra Mendonça Junior、Luciana Scotti、Marcus Tullius Scotti

  DOI：10.1016/j.molstruc.2019.126872

  日期：2019.12

  30 selenoglycolicamides and evaluated their potential anti-Leishmanial activity (L. amazonensis and L. donovani) through ligand- and structure-based virtual screening. A diverse set selected from the ChEMBL databanks of 818 structures (L. donovani) and 722 structures (L. amazonensis), with tested anti-Leishmanial activity against promastigotes forms were classified according to pIC50 values to generate

  摘要 利什曼病是一种被忽视的疾病，没有得到足够的治疗。我们创建了一个包含 30 种硒基乙醇酰胺的数据库，并通过基于配体和结构的虚拟筛选评估了它们潜在的抗利什曼原虫活性（L. amazonensis 和 L. donovani）。从 818 个结构 (L. donovani) 和 722 个结构 (L. amazonensis) 的 ChEMBL 数据库中选出的一组多样化的集合，根据 pIC50 值对测试的前鞭毛体形式的抗利什曼原虫活性进行分类，以生成和验证随机森林模型，该模型显示更高的统计指标值。从蛋白质数据库下载了四种不同的杜氏乳杆菌酶的结构，并将硒乙醇酰胺的结构提交给分子对接。计算机模拟研究使我们能够建议硒乙醇酰胺 18、25、27、26、6、10 和 7 可作为治疗利什曼原虫的潜在多靶点分子进行测试，表现出针对四种战略酶（拓扑异构酶 I、N-肉豆蔻酰基转移酶、亲环蛋白和 O-乙酰丝氨
• A Novel Approach to Pyrrolo[2,1-<i>b</i>]thiazoles
  作者：Anton V. Tverdokhlebov、Elizaveta V. Resnyanska、Andrey A. Tolmachev、Alexander P. Andrushko

  DOI：10.1055/s-2003-42451

  日期：——

  5-Aroyl-2-(dimethylamino)methylidene-2,3-dihydro-3-oxopyrrolo[2,1-b]thiazole-7-carboxylic acid esters, -7-carbonitriles and corresponding 7-hetaryl substituted derivatives were prepared. Thus, the substituted acetonitriles (XCH 2 CN, where X = CO 2 R, CN, hetaryl) were treated with mercaptoacetic acid yielding 2-(X-methylidene)thiazolidin-4-ones, which were N-alkylated with phenacyl bromides. Further

  制备了5-芳酰基-2-(二甲基氨基)亚甲基-2,3-二氢-3-氧代吡咯并[2,1-b]噻唑-7-羧酸酯、-7-腈和相应的7-杂芳基取代衍生物。因此，取代的乙腈（XCH 2 CN，其中 X = CO 2 R，CN，杂芳基）用巯基乙酸处理，产生 2-(X-亚甲基)噻唑烷-4-酮，其用苯酰溴进行 N-烷基化。用过量的DMF.POCl 3 络合物对所得化合物进一步甲酰化产生上述吡咯并[2,1-b]噻唑。
• Synthesis and docking studies of <i>N</i> ‐(5‐(alkylthio)‐1,3,4‐oxadiazol‐2‐yl)methyl)benzamide analogues as potential alkaline phosphatase inhibitors
  作者：Zafar Iqbal、Ambreen Iqbal、Zaman Ashraf、Muhammad Latif、Mubashir Hassan、Humaira Nadeem

  DOI：10.1002/ddr.21542

  日期：——

  hydrazide was then cyclized into 5‐substituted 1,3,4‐oxadiazole‐2‐thione 4. The intermediate 4 was then reacted with alkyl or aryl halides 5a–5i to afford the title compounds N‐(5‐(methylthio)‐1,3,4‐oxadiazol‐2‐yl)methyl)benzamides 6a–i. The bioassay results showed that compounds 6a–i exhibited good to excellent alkaline phosphatase inhibitory activity. The most potent activity was exhibited by the compound

  合成了一系列N-（5-（烷硫基）-1,3,4-恶二唑-2-基）甲基）苯甲酰胺6a-i作为碱性磷酸酶抑制剂。中间体5-取代的1,3,4-恶二唑-2-硫酮4是从马尿酸开始合成的。将第一步中的马尿酸转化为相应的甲酯2，其与水合肼反应后形成酰肼3。然后将马尿酸酰肼环化为5-取代的1,3,4-恶二唑-2-硫酮4。然后将中间体4与烷基或芳基卤化物5a-5i反应，得到标题化合物N-（5-（甲硫基）-1,3,4-恶二唑-2-基）甲基）苯甲酰胺6a–i。生物测定结果表明，化合物6a–i表现出良好至优异的碱性磷酸酶抑制活性。具有IC 50值为0.420μM的化合物6i表现出最有效的活性，而标准品（KH 2 PO 4）的IC 50值为2.80μM。针对碱性磷酸酶（PDBID 1EW2）进行了分子对接研究，以检查合成的化合物6a-1对靶蛋白的结合亲和力。对接结果显示三种化合物6c，6e和6i具有最大的结合相互作用，结合能值为-8
• Design, Synthesis and In Vitro Antimicrobial Activity of 6-(1H-Benzimidazol-2-yl)-3,5-dimethyl-4-oxo-2-thio-3,4-dihydrothieno[2,3-d]pyrimidines
  作者：Sergiy V. Vlasov、Olena D. Vlasova、Hanna I. Severina、Konstantin Yu. Krolenko、Oleksandr V. Borysov、Amjad Ibrahim M. Abu Sharkh、Vitaliy S. Vlasov、Victoriya A. Georgiyants

  DOI：10.3390/scipharm89040049

  日期：——

  from the P. aeruginosa. The results of antimicrobial activity screening revealed the antimicrobial properties for all of the studied molecules against both Gram-positive and Gram-negative bacteria and the Candida albicans fungal strain. The highest antimicrobial activity was determined for 2-[6-(1H-benzimidazol-2-yl)-3,5-dimethyl-4-oxo-3,4-dihydrothieno[2,3-d]pyrimidin-2-yl]thio}-N-(4-isopropylphenyl)acetamide

  细菌对许多已知抗生素的耐药性的快速发展迫使研究人员发现具有以前未知作用机制的候选抗菌药物，其中最相关的一种是抑制 tRNA（鸟嘌呤 37-N1）-甲基转移酶（TrmD）。在噻吩并嘧啶的甲酰胺衍生物系列中发现选择性 TrmD 抑制剂成为进一步修饰类似结构以开发有前途的抗菌剂的背景。作为这项研究的一部分，我们从 3,5-二甲基-4-氧代-2-硫代-1 H-噻吩并[2,3- d ]嘧啶和苯并咪唑部分开始构建杂环杂化物。2,3- d]嘧啶-6-羧酸，用作关键中间体。通过羧酸缩合制备的 6-(1 H -benzimidazol-2-yl)-3,5-dimethyl-2-thioxo-1 H -thieno[2,3 - d ]pyrimidin-4-one的杂化分子与邻苯二胺和芳基/杂芳基氯乙酰胺和苄基氯进一步烷基化，生成一系列S-烷基衍生物。所获得的S-烷基苯并咪唑-噻吩并嘧啶系列的分子对接研究结果表明它们对从铜绿假单胞菌中分离的